Skip to main content

Advertisement

SpringerLink
Log in

Consideration of Anticoagulation: Surgical Care for the Elderly in Current Geriatrics Reports

  • Surgical Care (F Luchette and R Gonzalez, Section Editors)
  • Published:
Current Geriatrics Reports Aims and scope Submit manuscript

Abstract

Introduction

The geriatric population in the USA is growing at a dramatic rate. As this segment of the population increases in number, surgical providers will increasingly treat and evaluate patients with age-specific needs that affect surgical or trauma management. Consequently, surgeons should be familiar with trends in prescribing oral anticoagulants (OACs), their association with outcomes, and the guidelines for reversing and prescribing these medications.

Results

Warfarin was the only oral anticoagulant available in the USA until 2010 when non-vitamin K antagonist oral anticoagulants (NOACs) were introduced to the market. Since then, they have rapidly gained a majority of the US market share. The implications of NOAC use on bleeding complications such as in traumatic brain injury (TBI) are unclear, but evidence suggests that NOACs may be safer than warfarin. Guidelines for anticoagulation reversal in life-threatening bleeding associated with warfarin are well established, but optimal utilization is evolving for most NOAC agents.

Conclusion

The use of anticoagulation therapy has changed dramatically over the last decade. These changes are multifactorial and include the increasing prevalence of OAC use, and the introduction of NOACs. Consequently, challenges associated with managing OAC in the elderly will only become more complicated over time. Surgical providers need to be aware of these changes and update their practice on the shifting epidemiology of this population, evolving guidelines, and new reversal agents.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. The Administration for Community Living. A Profile of Older Americans: 2017. United States of America, Department of Health and Human Services. 2018. Available at: https://acl.gov/sites/default/files/Aging%20and%20Disability%20in%20America/2017OlderAmericansProfile.pdf. Accessed 22 Jan 2019.

  2. Kirley K, Qato DM, Kornfield R, Stafford RS, Alexander GC. National trends in oral anticoagulant use in the United States, 2007 to 2011. Circulation: Cardiovascular Quality and Outcomes. 2012;5(5):615–21.

    Google Scholar 

  3. Berndtson AE, Coimbra R. The epidemic of pre-injury oral antiplatelet and anticoagulant use. Eur J Trauma Emerg Surg. 2014;40(6):657–69.

    Article  CAS  PubMed  Google Scholar 

  4. •• Zhu J, Alexander GC, Nazarian S, Segal JB, Wu AW. Trends and variation in oral anticoagulant choice in patients with atrial fibrillation, 2010–2017. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2018;38(9):907–20 The authors’ analysis of US medical and pharmacy claims between 2010 and 2017 demonstrated a dramatic increase in NOAC prescriptions since their introduction in 2010. Warfarin use decreased from a nearly 100% OAC market share in 2010 to only 21% in 2017. This decrease was accompanied by a concomitant increase in NOAC prescriptions, especially apixaban.

    Article  Google Scholar 

  5. National Center for Injury Prevention and Control (NCIPC). Leading Causes of Death by Age Group. Centers for Disease Control and Prevention, United States of America. 2016. Available at: https://www.cdc.gov/injury/images/lc-charts/leading_causes_of_death_age_group_2016_1056w814h.gif. Accessed 25 Feb 2019.

  6. Kuhne CA, Ruchholtz S, Kaiser GM, Nast-Kolb D. Mortality in severely injured elderly trauma patients—when does age become a risk factor? World J Surg. 2005;29(11):1476–82.

    Article  PubMed  Google Scholar 

  7. Ferrera PC, Bartfield JM, D'andrea CC. Outcomes of admitted geriatric trauma victims. Am J Emerg Med. 2000;18(5):575–80.

    Article  CAS  PubMed  Google Scholar 

  8. Faul M, Xu L, Wald MM, Coronado VG. Traumatic brain injury in the United States: emergency department visits, hospitalizations and deaths 2002–2006. Atlanta (GA): Centers for Disease Control and Prevention, National Center for Injury Prevention and Control; 2010. http://www.cdc.gov/traumaticbraininjury/pdf/blue_book.pdf. Accessed 2 Feb 2019.

    Book  Google Scholar 

  9. Ramanathan DM, McWilliams N, Schatz P, Hillary FG. Epidemiological shifts in elderly traumatic brain injury: 18-year trends in Pennsylvania. J Neurotrauma. 2012;29(7):1371–8. https://doi.org/10.1089/neu.2011.2197.

    Article  PubMed  Google Scholar 

  10. Centers for Disease Control and Prevention. "Important Facts about Falls." Centers for Disease Control and Prevention, United States of America. 2017. https://www.cdc.gov/homeandrecreationalsafety/falls/adultfalls.html. Accessed 28 Jan 2019.

  11. Gardner RC, Dams-O'Connor K, Morrissey MR, Manley GT. Geriatric traumatic brain injury: epidemiology, outcomes, knowledge gaps, and future directions. J Neurotrauma. 2018;35(7):889–906.

    Article  PubMed Central  PubMed  Google Scholar 

  12. Federal Highway Administration, Department of Transportation (US). Highway Statistics 2016. Washington (DC): FHWA; September 2018. Available at: https://www.fhwa.dot.gov/policyinformation/statistics/2016. Accessed 28 Jan 2019.

  13. Dossett LA, Riesel JN, Griffin MR, Cotton BA. Prevalence and implications of preinjury warfarin use: an analysis of the National Trauma Databank. Arch Surg (Chicago, Ill : 1960). 2011;146(5):565–70.

    Article  Google Scholar 

  14. Inui TS, Parina R, Chang DC, Inui TS, Coimbra R. Mortality after ground-level fall in the elderly patient taking oral anticoagulation for atrial fibrillation/flutter. J Trauma Acute Care Surg. 2014;76(3):642–50.

    Article  CAS  PubMed  Google Scholar 

  15. Chenoweth JA, Gaona SD, Faul M, Holmes JF, Nishijima DK. Incidence of delayed intracranial hemorrhage in older patients after blunt head trauma. JAMA Surg. 2018;153(6):570–5.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Tollefsen MH, Vik A, Skandsen T, Sandrød O, Deane SF, Rao V, et al. Patients with moderate and severe traumatic brain injury: impact of preinjury platelet inhibitor or warfarin treatment. World neurosurgery. 2018;114:e209–17.

    Article  PubMed  Google Scholar 

  17. Boltz MM, Podany AB, Hollenbeak CS, Armen SB. Injuries and outcomes associated with traumatic falls in the elderly population on oral anticoagulant therapy. Injury. 2015;46(9):1765–71.

    Article  PubMed  Google Scholar 

  18. Howard JL, Cipolle MD, Horvat SA, et al. Preinjury warfarin worsens outcome in elderly patients who fall from standing. J Trauma. 2009;66(6):1518–22 discussion1523–4.

    Article  CAS  PubMed  Google Scholar 

  19. Karni A, Holtzman R, Bass T, et al. Traumatic head injury in the anticoagulated elderly patient: a lethal combination. Am Surg. 2001;67(11):1098–100.

    CAS  PubMed  Google Scholar 

  20. Franko J, Kish KJ, O'Connell BG, et al. Advanced age and preinjury warfarin anticoagulation increase the risk of mortality after head trauma. J Trauma. 2006;61(1):107–10.

    Article  CAS  PubMed  Google Scholar 

  21. Bonville DJ, Ata A, Jahraus CB, et al. Impact of preinjury warfarin and antiplatelet agents on outcomes of trauma patients. Surgery. 2011;150(4):861–8.

    Article  PubMed  Google Scholar 

  22. Grandhi R, Harrison G, Voronovich Z, et al. Preinjury warfarin, but not antiplatelet medications, increases mortality in elderly traumatic brain injury patients. J Trauma Acute Care Surg. 2015;78(3):614–21.

    Article  CAS  PubMed  Google Scholar 

  23. Mina AA, Knipfer JF, Park DY, et al. Intracranial complications of preinjury anticoagulation in trauma patients with head injury. J Trauma. 2002;53(4):668–72.

    Article  CAS  PubMed  Google Scholar 

  24. Inamasu J, Nakatsukasa M, Miyatake S, Hirose Y. Influence of warfarin and low-dose aspirin on the outcomes of geriatric patients with traumatic intracranial hemorrhage resulting from ground-level fall. Geriatr Gerontol Int. 2012;12(4):667–72.

    Article  PubMed  Google Scholar 

  25. Pieracci FM, Eachempati SR, Shou J, Hydo LJ, Barie PS. Degree of anticoagulation, but not warfarin use itself, predicts adverse outcomes after traumatic brain injury in elderly trauma patients. J Trauma. 2007;63(3):525–30.

    Article  CAS  PubMed  Google Scholar 

  26. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955–62.

    Article  CAS  PubMed  Google Scholar 

  27. Chai-Adisaksopha C, Crowther M, Isayama T, Lim W. The impact of bleeding complications in patients receiving target-specific oral anticoagulants: a systematic review and meta-analysis. Blood. 2014;124(15):2450–8.

    Article  CAS  PubMed  Google Scholar 

  28. •• Graham DJ, Baro E, Zhang R, Liao J, Wernecke M, Reichman ME, et al. Comparative stroke, bleeding, and mortality risks in older Medicare patients treated with oral anticoagulants for nonvalvular atrial fibrillation. Am J Med. 2019;132(5):596–604.e11 This retrospective study of 448,944 US Medicare patients between 2010 and 2015 found a reduction in the risk of thromboembolic stroke, intracranial hemorrhage, and mortality for dabigatran, rivaroxaban, and apixaban when each was compared to warfarin. Reductions in intracranial hemorrhage for NOACs compared to warfarin ranged from 35%-62% (p<0.001). The harm reductions for NOACs were greatest for dabigatran and apixaban.

    Article  PubMed  Google Scholar 

  29. Lip GY, Keshishian A, Kamble S, Pan X, Mardekian J, Horblyuk R, et al. Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin. Thromb Haemost. 2016;115(05):975–86.

    Google Scholar 

  30. Kim IS, Kim HJ, Kim TH, Uhm JS, Joung B, Lee MH, et al. Non-vitamin K antagonist oral anticoagulants have better efficacy and equivalent safety compared to warfarin in elderly patients with atrial fibrillation: a systematic review and meta-analysis. J Cardiol. 2018;72(2):105–12.

    Article  PubMed  Google Scholar 

  31. Miller CS, Dorreen A, Martel M, Huynh T, Barkun AN. Risk of gastrointestinal bleeding in patients taking non–vitamin K antagonist oral anticoagulants: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2017;15(11):1674–83.

    Article  CAS  PubMed  Google Scholar 

  32. Bando S, Nishikado A, Hiura N, Ikeda S, Kakutani A, Yamamoto K, et al. Efficacy and safety of rivaroxaban in extreme elderly patients with atrial fibrillation: analysis of the Shikoku Rivaroxaban Registry Trial (SRRT). J Cardiol. 2018;71(2):197–201.

    Article  PubMed  Google Scholar 

  33. Paciaroni M, Agnelli G, Falocci N, Tsivgoulis G, Vadikolias K, Liantinioti C, et al. Early recurrence and major bleeding in patients with acute ischemic stroke and atrial fibrillation treated with non–vitamin-K Oral anticoagulants (RAF-NOAC s) study. J Am Heart Assoc. 2017;6(12):e007034.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Spinola MB, Riccardi A, Minuto P, Campodonico P, Motta G, Malerba M, Guiddo G, Lerza R. Hemorrhagic risk and intracranial complications in patients with minor head injury (MHI) taking different oral anticoagulants. Am J Emerg Med 2018;4. https://doi.org/10.1016/j.ajem.2018.12.003

  35. • Batey M, Hecht J, Callahan C, Wahl W. Direct oral anticoagulants do not worsen traumatic brain injury after low-level falls in the elderly. Surgery. 2018;164(4):814–9 This retrospective study of elderly trauma patients requiring neurosurgical care at 19 regional hospitals showed that patients on warfarin had more neurosurgical procedures compared to patients on a NOAC (18% vs. 2.8%, p<0.02). Warfarin users also required more red cell and plasma transfusions. However, there were no differences in mortality between patients taking warfarin or a NOAC. No neurologic outcomes were reported.

    Article  PubMed  Google Scholar 

  36. • Zeeshan M, Jehan F, O’Keeffe T, Khan M, Hamidi M, Gries L, et al. The novel oral anticoagulants (NOACs) have worse outcomes compared with warfarin in patients with intracranial hemorrhage after TBI. J Trauma Acute Care Surg. 2018;85(5):915–20 Zeeshan et al prospectively examined 210 patients with TBI on oral anticoagulation with two groups matched based on warfarin or NOAC use. NOAC users had a higher risk of intracranial hemorrhage progression, neurosurgical intervention, and TBI-associated mortality. Specific data on the NOAC agent used was not reported.

    Article  CAS  PubMed  Google Scholar 

  37. Holbrook A, Schulman S, Witt DM, Vandvik PO, Fish J, Kovacs MJ, et al. Evidence-based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2):e152S–84S.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Frontera JA, Lewin JJ III, Rabinstein AA, Aisiku IP, Alexandrov AW, Cook AM, et al. Guideline for reversal of antithrombotics in intracranial hemorrhage. Neurocrit Care. 2016;24(1):6–46.

    Article  CAS  PubMed  Google Scholar 

  39. Sarode R, Milling TJ Jr, Refaai MA, Mangione A, Schneider A, Durn BL, et al. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study. Circulation. 2013;128:1234–43.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Steiner T, Poli S, Griebe M, Husing J, Hajda J, Freiberger A, et al. Fresh frozen plasma versus prothrombin complex concentrate in patients with intracranial haemorrhage related to vitamin K antagonists (INCH): a randomised trial. Lancet Neurol. 2016;15:566–73.

    Article  CAS  PubMed  Google Scholar 

  41. Johansen M, Wikkelso A, Lunde J, Wetterslev J, Afshari A. Prothrombin complex concentrate for reversal of vitamin K antagonist treatment in bleeding and non-bleeding patients. Cochrane Database Syst Rev. 2015;7:CD010555.

    Google Scholar 

  42. Ko D, Razouki Z, Otis J, Marulanda-Londoño E, Hylek EM. Anticoagulation reversal in vitamin K antagonist–associated intracerebral hemorrhage: a systematic review. J Thromb Thrombolysis. 2018;23:1–1.

    Google Scholar 

  43. Burness CB. Idarucizumab: first global approval. Drugs. 2015;75(18):2155–61.

    Article  CAS  PubMed  Google Scholar 

  44. Glund S, Stangier J, Schmohl M, Gansser D, Norris S, van Ryn J, et al. Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial. Lancet. 2015;386(9994):680–90.

    Article  CAS  PubMed  Google Scholar 

  45. Pollack CV Jr, Reilly PA, Eikelboom J, Glund S, Verhamme P, Bernstein RA, et al. Idarucizumab for dabigatran reversal. N Engl J Med. 2015;373(6):511–20.

    Article  CAS  PubMed  Google Scholar 

  46. Heo YA. Andexanet alfa: first global approval. Drugs. 2018;20:1–7.

    Google Scholar 

  47. Siegal DM, Curnutte JT, Connolly SJ, Lu G, Conley PB, Wiens BL, et al. Andexanet alfa for the reversal of factor Xa inhibitor activity. N Engl J Med. 2015;373:2413–24.

    Article  CAS  PubMed  Google Scholar 

  48. • Connolly SJ, Milling TJ Jr, Eikelboom JW, Gibson CM, Curnutte JT, Gold A, et al. Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. N Engl J Med. 2016;375:1131–41 This is a prospective, multi-center, open-label study of the safety and efficacy of andexanet alfa as a reversal agent of a Xa inhibitor in the setting of acute major bleeding. At 12 hours post-infusion, 79% (95% CI: 64%–89%) had good or excellent clinical hemostasis but longer interval outcomes are not reported for hemostasis. Eighteen percent of patients had a thrombotic event within thirty days.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Ansell JE, Bakhru SH, Laulicht BE, Steiner SS, Grosso MA, Brown K, et al. Single-dose ciraparantag safely and completely reverses anticoagulant effects of edoxaban. Thromb Haemost. 2017;117(02):238–45.

    Article  PubMed  PubMed Central  Google Scholar 

  50. Hu TY, Vaidya VR, Asirvatham SJ. Reversing anticoagulant effects of novel oral anticoagulants: role of ciraparantag, andexanet alfa, and idarucizumab. Vasc Health Risk Manag. 2016;12:35–44.

    CAS  PubMed  PubMed Central  Google Scholar 

  51. Jacobs LG, Billett HH, Freeman K, Dinglas C, Jumaquio L. Anticoagulation for stroke prevention in elderly patients with atrial fibrillation, including those with falls and/or early-stage dementia: a single-center, retrospective, observational study. Am J Geriatr Pharmacother. 2009;7(3):159–66.

    Article  PubMed  Google Scholar 

  52. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJGM, Lip GYH. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138(5):1093–100.

    Article  PubMed  Google Scholar 

  53. Granziera S, Cohen AT, Nante G, Manzato E, Sergi G. Thromboembolic prevention in frail elderly patients with atrial fibrillation: a practical algorithm. Am Med Dir Assoc. 2015;16(5):358–64.

    Article  Google Scholar 

  54. Gage BF, Birman-Deych E, Kerzner R, Radford MJ, Nilasena DS, Rich MA. Incidence of intracranial hemorrhage in patients with atrial fibrillation who are prone to fall. Am J Med. 2005;118(6):612–7.

    Article  PubMed  Google Scholar 

  55. Monette J, Gurwitz JH, Rochon PA, Avorn J. Physician attitudes concerning warfarin for stroke prevention in atrial fibrillation: results of a survey of long-term care practitioners. J Am Geriatr Soc. 1997;45:1060–5.

    Article  CAS  PubMed  Google Scholar 

  56. Ogilvie IM, Newton N, Weiner SA, Cowell W, Lip GY. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med. 2010;123:638–45.

    Article  CAS  PubMed  Google Scholar 

  57. Zhu WG, Xiong QM, Hong K. Meta-analysis of CHADS2 versus CHA2DS2-VASc for predicting stroke and thromboembolism in atrial fibrillation patients independent of anticoagulation. Tex Heart Inst J. 2015;42(1):6–15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Fang MC, Go AS, Chang Y, Borowsky LH, Pomernacki NK, Udaltsova N, et al. A new risk scheme to predict warfarin-associated hemorrhage: the ATRIA Study. J Am Col Cardiol. 2011;58(4):395–401.

    Article  Google Scholar 

  59. Palareti G, Cosmi B. Bleeding with anticoagulation therapy—who is at risk, and how best to identify such patients. Thromb Haemost. 2009;102:268–78.

    Article  CAS  PubMed  Google Scholar 

  60. Gage BF, Yan Y, Milligan PE, et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J. 2006;1513:713–9.

    Article  Google Scholar 

  61. January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Conti JB, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;64(21):e1–76 Gall.

    Article  PubMed  Google Scholar 

  62. Roldan V, Marin F, Fernandez H, Manzano-Fernandez S, Gallego P, Vlades M, et al. Predictive value of the HAS-BLED and ATRIA bleeding scores for the risk of serious bleeding in a “real-world” population with atrial fibrillation receiving anticoagulant therapy. Chest. 2013;142:179–84.

    Article  Google Scholar 

  63. Roldan V, Marin F, Manzano-Fernandez S, Gallego P, Vilchez JA, Valdes M, et al. The HAS-BLED score has better prediction accuracy for major bleed than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation. J Am Coll Cardiol. 2013;62(23):2199–204.

    Article  PubMed  Google Scholar 

  64. Harvey NC, Johansson H, Odén A, Karlsson MK, Rosengren BE, Ljunggren Ö, et al. FRAX predicts incident falls in elderly men: findings from MrOs Sweden. Osteoporos Int. 2016;27(1):267–74.

    Article  CAS  PubMed  Google Scholar 

  65. Holloway KL, Kotowicz MA, Lane SE, Brennan SL, Pasco JA. FRAX (Aus) and falls risk: association in men and women. Bone. 2015;76:1–4.

    Article  PubMed  Google Scholar 

  66. Gleize F, Zmudka J, Lefresne Y, Serot JM, Berteaux B, Jouanny P. Fragility assessment in primary care: which tools for predicting what? Geriatr Psychol Nuropsychiatr Viell. 2015;13(3):289–97.

    Google Scholar 

  67. Sharifi F, Fakhrzadeh H, Memari A, Najafi B, Nazari N, Khoee MA, et al. Predicting risk of the fall among aged adult residents of a nursing home. Arch Gerontol Geriatr. 2015;61(2):124–30.

    Article  PubMed  Google Scholar 

  68. Lee J, Geller AI, Strasser DC. Analytical review: focus on fall screening assessments. PMR. 2013;5:609–21.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, Oregon Health & Science University, 3181 S.W. Sam Jackson Park Road, Mail Code: L611, Portland, OR, 97239, USA

    Jared R. Gallaher & Martin A. Schreiber

  2. Department of Surgery, University of North Carolina School of Medicine, 4001 Burnett-Womack Building, CB #7050, Chapel Hill, NC, 27599-7050, USA

    Joanna Grudziak

Authors
  1. Jared R. Gallaher
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Joanna Grudziak
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Martin A. Schreiber
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jared R. Gallaher.

Ethics declarations

Conflict of Interest

Jared R. Gallaher, Joanna Grudziak, and Martin A. Schreiber each declare no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Surgical Care

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gallaher, J.R., Grudziak, J. & Schreiber, M.A. Consideration of Anticoagulation: Surgical Care for the Elderly in Current Geriatrics Reports. Curr Geri Rep 8, 173–179 (2019). https://doi.org/10.1007/s13670-019-00290-w

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13670-019-00290-w

Keywords

Search

Navigation